title: Ceftibuten versus cefaclor for the treatment of bronchitis.
abstract: Ceftibuten is an oral third generation cephalosporin with potent antimicrobial activity against Enterobacteriaceae, beta-lactamase positive Haemophilus influenzae, Moraxella catarrhalis, Neisseria meningitidis, Neisseria gonorrheae, penicillin-susceptible pneumococci, and beta-hemolytic streptococci. To study the efficacy and safety of ceftibuten for treatment of bronchitis, 58 patients were randomized to therapy with either ceftibuten 400 mg once a day or cefaclor 250 mg every 8 h at a ratio of two to one. Of 45 clinically evaluable patients, 28 (87.5%) of the 32 ceftibuten patients and 12 (92.3%) of the 13 cefaclor patients were clinically improved or cured. Of 33 microbiologically evaluable patients, 21 (87.5%) of the 24 ceftibuten patients and eight (80%) of the ten cefaclor patients were cured. Of 56 patients evaluable for adverse effects, three (7.9%) of the 38 ceftibuten patients and one (5.6%) of the 18 cefaclor patients had adverse reactions. In this small study, once-daily ceftibuten appeared as safe and as effective as cefaclor for the treatment of bronchitis.
authors.affiliation: Medical Service, Veterans Administration Medical Center, Martinez, California USA 94553.
authors.forename: V A
authors.initials: VA
authors.lastname: Chirurgi
authors.forename: H
authors.initials: H
authors.lastname: Edelstein
authors.forename: S E
authors.initials: SE
authors.lastname: Oster
authors.forename: R
authors.initials: R
authors.lastname: Karp
authors.forename: K B
authors.initials: KB
authors.lastname: Cassano
authors.forename: S
authors.initials: S
authors.lastname: Aiken
authors.forename: P
authors.initials: P
authors.lastname: Krumpe
authors.forename: R E
authors.initials: RE
authors.lastname: McCabe
mesh_terms: D001419:Bacteria / Q000187:drug effects; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002433:Cefaclor / Q000008:administration & dosage / Q000627:therapeutic use*; D000077722:Ceftibuten; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests
chemical_list: D002511:Cephalosporins; D002433:Cefaclor; D000077722:Ceftibuten